AzTrials
AzTrials

Ureteric StoneURSL RCTNCT07788612

Comparison of Limited Fluoroscopy and Conventional URSL

A study testing Ureteroscopic Lithotripsy in people with Ureteric Stone, run by The University of Hong Kong at 1 site in Hong Kong.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Ureteroscopic lithotripsy (URSL) is the standard treatment for ureteric stones. Conventional URSL employs routine fluoroscopy for guidewire positioning, scope advancement, stent placement, and complication detection. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ureteric Stone
What is being tested?
Ureteroscopic Lithotripsy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteHong Kong
Study dates
1 Aug 2016to 31 Jul 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients 18 years of age or older who decided for URSL as the treatment for ureteric stone

Who cannot join

  • Patients who are unable to consent
  • No stone upon ureteroscopy
  • Known ureteric stricture or complicated ureteral anatomy
  • Stone in solitary kidney
  • Bilateral ureteric stones

Trial locations and contacts

1 site in 1 country.

Hong Kong1 site
  • Queen Mary Hospital

    Hong Kong, Hong Kong

Other trials in Hong Kong

About this study

Official title: Comparison of Limited Fluoroscopy Ureteroscopic Lithotripsy Against Conventional Ureteroscopic Lithotripsy, a 2 Center Randomized Controlled Trial

Background: Ureteroscopic lithotripsy (URSL) is the standard treatment for ureteric stones. Conventional URSL employs routine fluoroscopy for guidewire positioning, scope advancement, stent placement, and complication detection. While facilitating the procedure, this approach exposes patients and operating theatre staff to ionizing radiation, with attendant long-term health risks and occupational hazards from lead apron use. Retrospective and prospective case series have suggested that URSL can be performed safely with limited or no fluoroscopy using direct endoscopic visualization and tactile feedback. However, no randomized controlled trial has directly compared the stone clearance rates and radiation exposure between these two approaches.

Purpose: This two-center prospective randomized controlled trial aims to evaluate the feasibility and radiation exposure of limited-fluoroscopy URSL and to compare its complication profile, operative outcomes, and stone-free rates against conventional fluoroscopy-guided URSL.

Read more

Study question: Does a limited-fluoroscopy protocol significantly reduce intraoperative radiation dose without compromising the success rate, safety, or operative efficiency of ureteroscopic lithotripsy?

Methods: A total of 60 adult patients (≥18 years) with ureteric stones scheduled for URSL will be randomized in a 1:1 ratio to either the limited-fluoroscopy arm (fluoroscopy used only at surgeon's discretion for safety, with primary reliance on endoscopic landmarks) or the conventional arm (routine fluoroscopy throughout the procedure). The primary endpoint is radiation exposure (mGy). Secondary endpoints include stone-free rate at follow-up, operative time, intraoperative and postoperative complications, and need for auxiliary procedures.

Read the detailed description

Background and Rationale

Ureteric stone is a common urological condition. Ureteroscopic lithotripsy (URSL), with its minimal invasive nature and high stone clearance rate, has been the standard for treatment of ureteric stone. In conventional URSL, fluoroscopy is used routinely. Advantages of routine fluoroscopy include road mapping for difficult retrograde access in case of impacted stone or ureteric stricture, confirmation of position of guidewire or ureteric stent, and looking for complications such as extravasation of contrast or ureteric perforation. However, routine fluoroscopy also has its disadvantages. Patients suffering from ureteric colics already had exposure to various degrees of radiation during investigative procedures such as X-ray and computed tomography; routine fluoroscopy may further expose them to unnecessary radiation. Routine fluoroscopy also poses radiation hazards to surgeons and staff in the operating theatre. In addition, there are reports on occupational safety issues such as back pain attributed to lead apron. Furthermore, insertion of guidewire and ureteric stent can be accomplished by direct visualization through ureteroscope or cystoscope and tactile feedback instead of routine fluoroscopy.

In view of the potential advantage of URSL with limited fluoroscopy, different studies have looked into the feasibility of performing URSL with limited or even no fluoroscopy. Mandhani reported complete clearance of distal ureteric stones in 99 out of 110 patients by URSL with no fluoroscopy. Tepeler, Hsi and Olgin reported that URSLs can be performed safely and effectively with limited or no fluoroscopy. Unfortunately, all these studies are retrospective reviews or prospective series without randomization. More importantly, the stone clearance rate between limited fluoroscopy URSL and conventional URSL was never compared. Without a randomized controlled trial studying the two approaches of URSL for ureteric stone, it would be difficult to determine the superiority of one approach over the other.

Aim of Study

To evaluate feasibility and radiation exposure in limited-fluoroscopy ureteroscopic lithotripsy (URSL) and to compare its complication and outcome with conventional URSL.

Trial Design and Setting

This is a prospective randomized controlled trial conducted across two centers. Patients who undergo URSL for ureteric stone and consent to the study will be randomized to 2 groups: limited fluoroscopy URSL and conventional URSL with routine fluoroscopy.

In the limited fluoroscopy URSL group, guidewire insertion, endoscopic advancement, stone fragmentation and ureteric stent placement will be completed under direct endoscopic view and tactile feedback. Stand-by fluoroscopy will be available and the operating surgeon can always obtain fluoroscopic image during the procedure in the same way as conventional URSL at his discretion. Upon completion of the operation, limited retrograde pyelogram will be performed to rule out complication and to confirm the position of ureteral stent.

In the conventional URSL group, fluoroscopy will be used upon guidewire insertion, endoscopic advancement, stone fragmentation and ureteral stent placement. Completion retrograde pyelogram will be performed to look for extravasation.

Study Population

Inclusion criteria include all patients 18 years of age or older who decided for URSL as the treatment for ureteric stone. Exclusion criteria include patients who are unable to consent, no stone upon ureteroscopy, known ureteric stricture or complicated ureteral anatomy, stone in solitary kidney and bilateral ureteric stones. Patients are free to withdraw from the study at any time and will continue to be managed as per usual. Their data will be used and analyzed according to the intention-to-treat principle.

Data Collection

Data collected from patients will include demographic data, laterality, location, size and number of stone, laser energy used, need of stent placement during operation, operative time and outcome, radiation exposure, intra-operative and post-operative complication, stone free rate and need of auxiliary procedure upon follow up.

Statistical Analysis

The sample size calculation rationale is based on the following: the mean radiation exposure of conventional URSL was 46.4 mGy and a mean radiation dose of 1.1 mGy in limited fluoroscopy URSL was reported. To prove the difference in radiation dose with estimated 90% power and a prediction of 20% dropout, the calculated sample size required for the primary endpoint is 60 patients, with 30 patients in each group.

Patient demographic data including age and sex, laterality, location, size and number of stone, laser energy used, need of stent placement during operation, operative time and outcome, radiation exposure, intra-operative and post-operative complication, stone free rate and need of auxiliary procedure upon follow up will be analyzed statistically. The chi-square statistic is used for categorical variables and the t-test is used for continuous variables to compare difference between the two groups with statistical significance considered at p<0.05. The intention-to-treat principle is adopted. All participants are analyzed in their assigned groups. SPSS will be used for all statistical analyses.

Primary End-point

Radiation exposure of limited-fluoroscopy URSL

Secondary End-points

Success rate of limited-fluoroscopy URSL

Operative time

Complication

Stone free rate

Need of auxiliary procedure

Data Access, Handling and Ethics

To protect patient privacy, all research data will be handled in line with Hospital Authority's or Hospital's policy in handling/storage/destruction of patients' medical records. They would be locked in cabinets where the department/ward keep patients' medical records. Electronic data would be saved in secured computer of the hospital with restricted access. USB Device would not be used for patient information for personal data. Personal data (name, HKID, address and any other personal identifiable information) should not be recorded on the projects' data sheets or electronic files. A study code will be used. Any documents or electronic files containing personal identifiable information would be considered as part of the medical record and will be dealt with the same stringent regulations of security according to the hospital policies. The principal investigator/co-investigator will be responsible for the execution of data protection. This study complies with the requirements of ICH-GCP.

There is no conflict of interest in this study. Previous retrospective studies and prospective series demonstrated feasibility and safety of limited/no fluoroscopy URSL. In our current trial, fluoroscopy will be provided at the surgeon's discretion in the limited fluoroscopy arm to ensure smooth and safe URSL. No additional financing or insurance requirements are necessary.

Conditions
Ureteric Stone
Being tested
Ureteroscopic Lithotripsy
Keywords
Ureteric stone, limited-fluoroscopy ureteroscopic lithotripsy
Medical subject headings
Ureterolithiasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ureteroscopic LithotripsyProcedure or surgery

    Also called Holmium laser lithotripsy, Endoscopic stone fragmentation, URSL

    Surgical procedure performed under general or regional anaesthesia using a semi-rigid or flexible ureteroscope to access the ureteric stone. Stone fragmentation is achieved using a holmium:YAG laser with energy settings determined by stone composition and size. Fragments may be retrieved using endoscopic baskets or forceps. Ureteric stent placement and retrograde pyelography are performed as clinically indicate

Study groups in NCT07788612
Study groupRoleWhat they receive
Limited-Fluoroscopy URSLExperimentalPatients undergo ureteroscopic lithotripsy with fluoroscopy reserved for safety backup only. Guidewire insertion, endoscopic advancement, stone fragmentation, and ureteric stent placement are performed under direct endoscopic visualization and tactile feedback. Stand-by fluoroscopy is available at the operating surgeon's discretion. Upon completion, a limited retrograde pyelogram is performed to exclude extravasation and confirm stent position.
Receives: Procedure: Ureteroscopic Lithotripsy
Conventional Fluoroscopy-Guided URSLActive comparatorPatients undergo ureteroscopic lithotripsy with routine fluoroscopy employed at standard procedural steps: during guidewire insertion, endoscopic advancement, stone fragmentation, and ureteric stent placement. A completion retrograde pyelogram is routinely performed to look for contrast extravasation or ureteric perforation.
Receives: Procedure: Ureteroscopic Lithotripsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total intraoperative radiation exposure in limited-fluoroscopy versus conventional URSL

    Measured: Intraoperative

Secondary outcomes (5)
  1. Success rate of limited-fluoroscopy URSL

    Measured: Intraoperative

  2. Operative time

    Total operative duration measured from cystoscope insertion to completion of stent placement or final endoscopic check.

    Measured: Intraoperative

  3. Intraoperative and postoperative complications

    Measured: Intraoperative and up to 30 days postoperatively

  4. Stone-free rate

    Proportion of patients with complete stone clearance as determined by imaging at post-operative follow-up.

    Measured: At 4 weeks postoperatively

  5. Need for auxiliary procedures

    Measured: Up to 3 months postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Aug 2026
  2. Study start1 Aug 2016
  3. Primary completion31 Jan 2017
  4. Study completion31 Jul 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07788612
Sponsor's protocol ID
UW 17-178
Acronym
URSL RCT
Status last verified
Aug 2016
First submitted
20 Aug 2026
Last updated
26 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Lipkin ME, Wang AJ, Toncheva G, Ferrandino MN, Yoshizumi TT, Preminger GM. Determination of patient radiation dose during ureteroscopic treatment of urolithiasis using a validated model. J Urol. 2012 Mar;187(3):920-4. doi: 10.1016/j.juro.2011.10.159. Epub 2012 Jan 20.

    PubMed 22264465
  • Shrimpton PC, Hillier MC, Lewis MA, Dunn M. National survey of doses from CT in the UK: 2003. Br J Radiol. 2006 Dec;79(948):968-80. doi: 10.1259/bjr/93277434.

    PubMed 17213302
  • Ordon M, Urbach D, Mamdani M, Saskin R, D'A Honey RJ, Pace KT. The surgical management of kidney stone disease: a population based time series analysis. J Urol. 2014 Nov;192(5):1450-6. doi: 10.1016/j.juro.2014.05.095. Epub 2014 May 24.

    PubMed 24866599
  • Weld LR, Nwoye UO, Knight RB, Baumgartner TS, Ebertowski JS, Stringer MT, Kasprenski MC, Weld KJ. Fluoroscopy time during uncomplicated unilateral ureteroscopy for urolithiasis decreases with urology resident experience. World J Urol. 2015 Jan;33(1):119-24. doi: 10.1007/s00345-014-1264-y. Epub 2014 Feb 23.

    PubMed 24562314
  • Sfoungaristos S, Lorber A, Gofrit ON, Yutkin V, Landau EH, Pode D, Duvdevani M. Surgical experience gained during an endourology fellowship program may affect fluoroscopy time during ureterorenoscopy. Urolithiasis. 2015 Aug;43(4):369-74. doi: 10.1007/s00240-015-0774-4. Epub 2015 Apr 18.

    PubMed 25894628
  • Brink JA, Amis ES Jr. Image Wisely: a campaign to increase awareness about adult radiation protection. Radiology. 2010 Dec;257(3):601-2. doi: 10.1148/radiol.10101335. No abstract available.

    PubMed 21084410
  • Rebuck DA, Coleman S, Chen JF, Casey JT, Perry KT, Nadler RB. Extracorporeal shockwave lithotripsy versus ureteroscopy: a comparison of intraoperative radiation exposure during the management of nephrolithiasis. J Endourol. 2012 Jun;26(6):597-601. doi: 10.1089/end.2011.0185. Epub 2011 Oct 4.

    PubMed 21970366
  • Mohey A, Alhefnawy M, Mahmoud M, Gomaa R, Soliman T, Ahmed S, Noureldin YA. Fluoroless-ureteroscopy for definitive management of distal ureteral calculi: randomized controlled trial. Can J Urol. 2018 Feb;25(1):9205-9209.

    PubMed 29524976
  • Olgin G, Smith D, Alsyouf M, Arenas JL, Engebretsen S, Huang G, Arnold DC 2nd, Baldwin DD. Ureteroscopy Without Fluoroscopy: A Feasibility Study and Comparison with Conventional Ureteroscopy. J Endourol. 2015 Jun;29(6):625-9. doi: 10.1089/end.2014.0237. Epub 2015 Jan 6.

    PubMed 25562139
  • Hsi RS, Harper JD. Fluoroless ureteroscopy: zero-dose fluoroscopy during ureteroscopic treatment of urinary-tract calculi. J Endourol. 2013 Apr;27(4):432-7. doi: 10.1089/end.2012.0478. Epub 2013 Feb 15.

    PubMed 23194092
  • Mandhani A, Chaudhury H, Gupta N, Singh HK, Kapoor R, Kumar A. Is fluoroscopy essential for retrieval of lower ureteric stones? Urol Int. 2007;78(1):70-2. doi: 10.1159/000096938.

    PubMed 17192736
  • Aboutaleb HA, Ali TA, Gawish M, Omar MK. Fluoroscopy-free double-J stent placement through ureteroscope working channel postuncomplicated ureteroscopic laser lithotripsy: A novel technique. Urol Ann. 2019 Jan-Mar;11(1):39-45. doi: 10.4103/UA.UA_59_18.

    PubMed 30787569
  • Tepeler A, Armagan A, Akman T, Silay MS, Akcay M, Basibuyuk I, Erdem MR, Onol SY. Is fluoroscopic imaging mandatory for endoscopic treatment of ureteral stones? Urology. 2012 Nov;80(5):1002-6. doi: 10.1016/j.urology.2012.02.082. Epub 2012 Jul 31.

    PubMed 22854137
  • Danilovic A, Nunes E, Lipkin ME, Ferreira T, Torricelli FCM, Marchini GS, Srougi M, Nahas WC, Mazzucchi E. Low Dose Fluoroscopy During Ureteroscopy Does Not Compromise Surgical Outcomes. J Endourol. 2019 Jul;33(7):527-532. doi: 10.1089/end.2018.0722.

    PubMed 30793920
  • Greene DJ, Tenggadjaja CF, Bowman RJ, Agarwal G, Ebrahimi KY, Baldwin DD. Comparison of a reduced radiation fluoroscopy protocol to conventional fluoroscopy during uncomplicated ureteroscopy. Urology. 2011 Aug;78(2):286-90. doi: 10.1016/j.urology.2010.11.020. Epub 2011 Jan 22.

    PubMed 21256553

Questions about this trial

What is this clinical trial studying?

A study testing Ureteroscopic Lithotripsy in people with Ureteric Stone, run by The University of Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total intraoperative radiation exposure in limited-fluoroscopy versus conventional URSL (time frame: Intraoperative). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07788612, which also lists 20 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in